Cargando…
Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy
Rimeporide, a first-in-class sodium/proton exchanger Type 1 inhibitor (NHE-1 inhibitor) is repositioned by EspeRare for patients with Duchenne Muscular Dystrophy (DMD). Historically, NHE-1 inhibitors were developed for cardiac therapeutic interventions. There is considerable overlap in the pathophysi...
Autores principales: | Previtali, Stefano C., Gidaro, Teresa, Díaz-Manera, Jordi, Zambon, Alberto, Carnesecchi, Stephanie, Roux-Lombard, Pascale, Spitali, Pietro, Signorelli, Mirko, Szigyarto, Cristina Al-Khalili, Johansson, Camilla, Gray, Julian, Labolle, Delphine, Porte Thomé, Florence, Pitchforth, Jacqueline, Domingos, Joana, Muntoni, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482441/ https://www.ncbi.nlm.nih.gov/pubmed/32535224 http://dx.doi.org/10.1016/j.phrs.2020.104999 |
Ejemplares similares
-
Biomarkers of Duchenne muscular dystrophy: current findings
por: Szigyarto, Cristina Al-Khalili, et al.
Publicado: (2018) -
Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy
por: Strandberg, Kristin, et al.
Publicado: (2020) -
Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy
por: Signorelli, Mirko, et al.
Publicado: (2019) -
Penalized regression calibration: A method for the prediction of survival outcomes using complex longitudinal and high‐dimensional data
por: Signorelli, Mirko, et al.
Publicado: (2021) -
Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers
por: Johansson, Camilla, et al.
Publicado: (2023)